Amedisys, Inc. (NASDAQ:AMED) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its stake in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 4.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 361,812 shares of the health services provider's stock after buying an additional 15,730 shares during the period. Charles Schwab Investment Management Inc. owned about 1.10% of Amedisys worth $32,849,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. National Bank of Canada FI lifted its position in shares of Amedisys by 119.0% in the third quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider's stock valued at $5,365,000 after acquiring an additional 30,213 shares in the last quarter. ABC Arbitrage SA purchased a new position in Amedisys in the 4th quarter valued at about $2,522,000. Geode Capital Management LLC boosted its stake in shares of Amedisys by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider's stock worth $54,746,000 after purchasing an additional 7,071 shares during the last quarter. Quarry LP purchased a new stake in shares of Amedisys during the third quarter worth about $2,569,000. Finally, Holocene Advisors LP grew its holdings in shares of Amedisys by 391.4% during the third quarter. Holocene Advisors LP now owns 79,036 shares of the health services provider's stock worth $7,628,000 after buying an additional 62,953 shares in the last quarter. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, Stephens restated an "equal weight" rating and set a $101.00 target price on shares of Amedisys in a research report on Tuesday, March 4th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Amedisys currently has a consensus rating of "Hold" and a consensus price target of $100.75.

Amedisys Trading Down 0.0 %

Shares of NASDAQ AMED traded down $0.03 on Thursday, reaching $92.87. 144,564 shares of the company traded hands, compared to its average volume of 377,074. The stock has a market capitalization of $3.05 billion, a PE ratio of 36.84, a P/E/G ratio of 1.78 and a beta of 0.76. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The company has a 50 day moving average of $92.19 and a 200 day moving average of $92.67.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing the consensus estimate of $1.05 by ($0.09). The company had revenue of $598.05 million for the quarter, compared to analyst estimates of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. On average, equities research analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.